Established 2016|Australia's longest-standing research supplier|Trusted by 4,000+ researchers & labs|Batch-tested · Fast AU-wide dispatch
VCP Australia
Sign In
Peptides — Growth Hormone Axis

Tesamorelin

A stabilised GHRH analogue (trans-3-hexenoyl-GHRH 1-44) studied in clinical trials of visceral adipose tissue in HIV-associated lipodystrophy.

Education Hub

Pre-clinical mechanism

Binds the pituitary GHRH receptor with increased plasma stability versus native GHRH 1-44, producing pulsatile GH release and downstream IGF-1 elevation.

Key pre-clinical findings

  • Phase-3 clinical pharmacology: reduction in visceral adipose tissue measured by CT versus placebo in adults with HIV-associated lipodystrophy (Falutz et al., 2007).

Primary literature

Metabolic effects of a growth hormone-releasing factor in patients with HIV

Falutz J, Allas S, Blot K, et al. · New England Journal of Medicine · 2007

Research and educational use only. This page summarises publicly available pre-clinical literature for educational and scientific reference. It is not medical, clinical, dosing or therapeutic advice. Nothing on this page implies that any VCP Australia product is approved, certified, safe, effective, suitable for a particular purpose, or intended for human or animal consumption.

Research-Use Notice

Products displayed on this website may be intended for laboratory, analytical or research purposes only where applicable. They are not intended to diagnose, treat, cure or prevent any disease. They are not supplied for human or animal consumption unless expressly stated and lawfully permitted. Customers are responsible for understanding and complying with all applicable laws and regulations. Product information is provided for informational purposes only and does not constitute medical advice.

Read Full Disclaimer